$INNV 6-bagger corrected $0.47 OTC Bottom 4/1
Post# of 98044
Posted On: 08/21/2016 9:11:08 AM
$INNV 6-bagger corrected $0.47
OTC
Bottom 4/11/16 $0.088
Website
8/19/15
Innovus Pharma Announces the Approval of the Product Licenses for Zestra® , Zestra Glide®, EjectDelay® and Sensum+® by the Indian FDA (Directorate General of Health Services) through its Partner Khandelwal Laboratories
Shares Outstanding 87.18M
Float 58.81M
% Held by Insiders N/A
Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The companys pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. is headquartered in San Diego, California
OTC
Bottom 4/11/16 $0.088
Website
8/19/15
Innovus Pharma Announces the Approval of the Product Licenses for Zestra® , Zestra Glide®, EjectDelay® and Sensum+® by the Indian FDA (Directorate General of Health Services) through its Partner Khandelwal Laboratories
Shares Outstanding 87.18M
Float 58.81M
% Held by Insiders N/A
Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The companys pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. is headquartered in San Diego, California
(0)
(0)Scroll down for more posts ▼